[PDF] Top 20 El compromiso organizacional: un valor personal y empresarial en el marketing interno
Has 10000 "El compromiso organizacional: un valor personal y empresarial en el marketing interno" found on our website. Below are the top 20 most common "El compromiso organizacional: un valor personal y empresarial en el marketing interno".
<p>Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy</p>
... Abstract: Lumacaftor-ivacaftor is a combination of two small molecule therapies targeting the basic defect in cystic fi brosis (CF) at a cellular ...potentiator. Lumacaftor, the corrector, ... See full document
8
<p>Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy</p>
... long-term therapy is restriction of total dietary fat intake to <10-15% of daily calories (15 to 20g per ...RNA therapy to apoC3 as well as other approaches to modulating triglycerides are in ... See full document
6
<p>Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy</p>
... We provide a comprehensive overview of danoprevir to highlight its preclinical discovery, clinical ef fi cacy, pharma- cokinetics, and pharmacodynamics. Based on clinical trials at phases 2 and 3, SVR12 of the ... See full document
6
<p>Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy</p>
... composite primary efficacy end point defined a responder as a weekly improvement in 9 out of total 12 weeks, including 3 of the last 4 weeks. A weekly responder was defined as a subject who had > 3 CSBMs per week and ... See full document
79
<p>Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy</p>
... DAA therapy failures, 28/30 ...explicit treatment options at this time. For these patients, alternative treatment options, including off-label DAA combi- nations without an NS3/4A inhibitor such as ... See full document
16
<p>Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy</p>
... took place from March 2015 until January 2016 at 40 sites across 10 countries with enrollment of 124 patients with R/R MCL who had received up to 5 prior lines of ...Previous treatment with BTKi was not ... See full document
7
<p>Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy</p>
... the treatment of angioedema attacks are to be easy to assume in the terms of time interval between two treatments, have an easy route of administration, reach a complete effectiveness in the control of attacks and ... See full document
5
Delafloxacin: design, development and potential place in therapy
... the treatment of these and other ...possible place in the current antimicrobial outlook and its possible use in other infectious contexts are also ... See full document
32
<p>Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy</p>
... in Treatment of Type 2 Diabetes) included a series of Phase IIIA RCTs (SUSTAIN 1–5), designed to evaluate the efficacy and safety of semaglutide SC administered subcutaneously once a week in a range of people with ... See full document
38
CT-P13: design, development, and place in therapy
... Abstract: The introduction of biological agents has revolutionized the management of many life-threatening and debilitating immune-mediated diseases. Because of the high cost of biological drugs and their patent ... See full document
16
Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
... An alternative to gene therapy, which shows more promise, is the development of small-molecule compounds that target specific CFTR mutations. These exciting new developments are based on improved ... See full document
8
Plitidepsin: design, development, and potential place in therapy
... and, at present, is manufactured by total synthesis and com- mercialized as plitidepsin. Its antitumor activity, observed in preclinical in vitro and in vivo studies, has prompted numerous clinical trials during the last ... See full document
8
<p>Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis</p>
... like lumacaftor/ivacaftor combination the lung function improvement with tezacaftor/ivacaftor is modest, at best, especially as compared to the improve- ments seen with ivacaftor in patients ... See full document
12
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation
... that ivacaftor was well tolerated and the authors recommended follow-up clinical trials to further investigate the drug’s efficacy in CF patients with the G551D- CFTR ...between treatment groups and the ... See full document
16
Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor
... with ivacaftor in children with the G551D-CFTR ...between ivacaftor and linear ...pubertal development/ progression and pubertal peak height velocity suggests a significant delay in children with ... See full document
21
Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
... US, lumacaftor/ivacaftor was approved receiving or- phan drug ...for development of drugs for rare diseases and provided incentives that increased revenues post-approval by decreasing ... See full document
7
Targeted therapies to improve CFTR function in cystic fibrosis
... CFTR-modulating treatment are yet to be completely elucidated. Additionally, ivacaftor is an extremely ex- pensive drug that costs in the region of US$300,000 an- nually per ...because treatment ... See full document
95
Cystic fibrosis and the relevance of the whole body vibration exercises in oscillating platforms: a short review
... daily treatment burden of CF is high and people may spend up to 2 h per day on a wide range of CF therapies, including taking medications and undergoing physiotherapy treatments such as regular airway clear- ance ... See full document
115
A NEW RP-UPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF IVACAFTOR AND LUMACAFTOR
... of Ivacaftor and 100mg of Lumacaftor in 100ml volumetric flask and add 70ml of mobile phase then sonicated it for 30min intermittent shacking after 30min make up ... See full document
17
Gene therapy for the treatment of cystic fibrosis
... lungs are normal at birth, indicating a potential therapeutic window. However, in practice, the airways are in fact very difficult targets for gene therapy. The mucociliary escala- tor has evolved to keep foreign ... See full document
11
Related subjects